Figure 403: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients worsened – grades 1 and 2 pressure ulcers

	Ointmo	Petrolatum			Peto Odds Ratio	P	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Pe	to, Fix	ed, 95%	6 CI	
Kuflik 2001	0	10	6	9	100.0%	0.05 [0.01, 0.35]	_				
Total (95% CI)		10		9	100.0%	0.05 [0.01, 0.35]	~	-			
Total events	0		6								
Heterogeneity: Not app	plicable						0.001	1.1	1 1		1000
Test for overall effect:	Z = 3.04 (P = 0.0	02)				Favours oin			-	trolatum

Figure 404: Topical ointment with petrolatum versus petrolatum (base component) – proportion of patients worsened – grades 2 pressure ulcers

	Ointment		Petrolatum		Peto Odds Ratio		Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Kuflik 2001	0	5	3	3	100.0%	0.02 [0.00, 0.38]	+
Total (95% CI)		5		3	100.0%	0.02 [0.00, 0.38]	
Total events	0		3				
Heterogeneity: Not app	olicable						0.01 0.1 1 10 100
Test for overall effect:	Z = 2.65 (P = 0.00	08)				0.01 0.1 1 10 100 Favours ointment Favours petrolatum

Figure 405: Topical ointment with petrolatum versus petrolatum (base component) – mortality

	Ointme	Ointment Petrolatum			Peto Odds Ratio			Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI			Peto, Fixe	ed, 95%	6 CI	
Kuflik 2001	0	10	0	9		Not estimable						
Total (95% CI)		10		9		Not estimable						
Total events	0		0									
Heterogeneity: Not app	olicable						0.01		4 .	!	10	100
Test for overall effect:	Not applic	able					0.01 Favoi	0. urs (i ointment	Favou	rs pet	100 rolatum

I.2.7.12 Zinc oxide versus streptokinase-streptodornase

Figure 406: Zinc oxide versus streptokinase-streptodornase – median percentage reduction in ulcer area

	Zinc	Zinc oxide Streptokinase-streptode				odorn		Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	l	IV, Fixed	1, 95% CI		
Agren 1985	2.4	0	14	-18.7	0	14		Not estimable					
Total (95% CI)			14			14		Not estimable	,				
Heterogeneity: Not as Test for overall effect			le						-100 Favours	-50 experimental	0 50	-	100

Figure 407: Zinc oxide versus streptokinase-streptodornase – proportion of patients with an infection




Figure 408: Zinc oxide versus streptokinase-streptodornase – proportion of patients with skin reaction

	Zinc ox	cide	Streptokinase-strep	ptodorn		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Agren 1985	0	14	1	14	100.0%	0.14 [0.00, 6.82]	
Total (95% CI)		14		14	100.0%	0.14 [0.00, 6.82]	
Total events	0		1				
Heterogeneity: Not as	oplicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 1.00 (P = 0.3	2)				Favours zinc oxide Favours streptokinase

Figure 409: Zinc oxide versus streptokinase-streptodornase – mortality

	Zinc ox	ride	Streptokinase-streptodorn		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	l Peto, Fix	red, 95% CI	
Agren 1985	0	14	0	14		Not estimable			
Total (95% CI)		14		14		Not estimable			
Total events	0		0						
Heterogeneity: Not app	olicable						0.01 0.1	1 10	100
Test for overall effect:	Not applic	able					Favours zinc oxide		

I.2.7.13 Oxyquinoline versus A&D treatment

Figure 410: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (all grades)

	Oxyquin	Oxyquinoline A&D treatment			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	43	86	21	51	100.0%	1.21 [0.82, 1.79]	_
Total (95% CI)		86		51	100.0%	1.21 [0.82, 1.79]	-
Total events	43		21				
Heterogeneity: Not a	pplicable						02 05 1 2 5
Test for overall effect	Z = 0.98 (F	P = 0.33)				Favours A&D treatment Favours oxyguinoline

Figure 411: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (grade I)

	Oxyquinoline A&D treatment			Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	23	41	16	28	100.0%	0.98 [0.65, 1.49]	-
Total (95% CI)		41		28	100.0%	0.98 [0.65, 1.49]	-
Total events	23		16				
Heterogeneity: Not as	pplicable						02 05 1 2 5
Test for overall effect: Z = 0.09 (P = 0.93)							Favours A&D treatment Favours oxyquinoline

Figure 412: Oxyquinoline versus A&D treatment – proportion of ulcers completely healed (grade II)

	•							
	Oxyquin	oline	A&D treat	tment		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Gerding 1993	20	45	5	23	100.0%	2.04 [0.88, 4.74]	+	_
Total (95% CI)		45		23	100.0%	2.04 [0.88, 4.74]	-	
Total events	20		5					
Heterogeneity: Not ap							0.01 0.1 1 10 100	
Test for overall effect:	Z = 1.67 (F	P = 0.10)				Favours A&D treatment Favours oxyguinoline	

Figure 413: Oxyquinoline versus A&D treatment – proportion of ulcers improved on day 15 (grade I)

	Oxyquin	oline	A&D treat	tment		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	15	41	6	28	100.0%	1.71 [0.76, 3.86]	+
Total (95% CI)		41		28	100.0%	1.71 [0.76, 3.86]	-
Total events	15		6				
Heterogeneity: Not ap	plicable						0.01 0.1 1 10 100
Test for overall effect	Z = 1.29 (F	P = 0.20)				Favours A&D treatment Favours oxyquinoline

Figure 414: Oxyquinoline versus A&D treatment – proportion of ulcers improved on day 22 (grade II)

	•						
	Oxyquin	oline	A&D trea	tment		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	19	45	8	23	100.0%	1.21 [0.63, 2.34]	_
Total (95% CI)		45		23	100.0%	1.21 [0.63, 2.34]	-
Total events	19		8				
Heterogeneity: Not a	pplicable						01 02 05 1 2 5 10
Test for overall effect	Z = 0.58 (F	P = 0.56)				Favours A&D treatment Favours oxyquinoline

Figure 415: Oxyquinoline versus A&D treatment – proportion of ulcers not changed on day 15 (grade I)

	Oxyquinoline A&D treatment			Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Gerding 1993	4	41	4	28	100.0%	0.68 [0.19, 2.51]	_
Total (95% CI)		41		28	100.0%	0.68 [0.19, 2.51]	-
Total events	4		4				
Heterogeneity: Not a	pplicable						0.01 0.1 1 10 100
Test for overall effect	Z = 0.58 (F	P = 0.57)				Favours oxyquinoline Favours A&D treatment

Figure 416: Oxyquinoline versus A&D treatment – proportion of ulcers not changed on day 22 (grade II)

		•								
		, ,		A&D trea	atment		Risk Ratio	Risk Ratio		
Study or S	Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI	
Gerding 1	993	5	45	7	23	100.0%	0.37 [0.13, 1.02]	_		_
Total (95%	CI)		45		23	100.0%	0.37 [0.13, 1.02]	-		
Total even	ts	5		7						
Heterogen	eity: Not ap	plicable						0.01 0.1	10 100	4
Test for ov	erall effect.	Z = 1.91 (F	P = 0.06)					Favours A&D treatmen	-

Figure 417: Oxyquinoline versus A&D treatment – proportion of ulcers worsened on day 15 (grade I)

10	•						
	Oxyquin	oline	A&D treatment			Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Gerding 1993	0	41	2	28	100.0%	0.08 [0.00, 1.41]	
Total (95% CI)		41		28	100.0%	0.08 [0.00, 1.41]	
Total events	0		2				
Heterogeneity: Not ap	plicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 1.72 (F	P = 0.08)				Favours oxyguinoline Favours A&D treatment

Figure 418: Oxyquinoline versus A&D treatment – proportion of ulcers worsened on day 22 (grade II)

10	•							
	Oxyquin	oline	A&D trea	tment		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Gerding 1993	1	45	3	23	100.0%	0.17 [0.02, 1.55]		
Total (95% CI)		45		23	100.0%	0.17 [0.02, 1.55]		
Total events	1		3					
Heterogeneity: Not ap	plicable						0.01 0.1 1 10 100	
Test for overall effect:	Z = 1.57 (F	P = 0.12)				Favours oxyguinoline Favours A&D treatment	

Figure 419: Oxyquinoline versus A&D treatment – mean days to complete healing (all grades)

	Oxyquinoline		ne	A&D t	reatm	ent		Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
Gerding 1993	7.23	4.15	86	8.62	5.16	51	100.0%	-1.39 [-3.06, 0.28]				
Total (95% CI)			86			51	100.0%	-1.39 [-3.06, 0.28]				
Heterogeneity: Not ap			10\						-2 -1 0 1 2			
Test for overall effect:	2 = 1.04	(P = t).10)						Favours oxyquinoline Favours A&D treatment			

Figure 420: Oxyquinoline versus A&D treatment – mean days to complete healing (grade I)

	Oxyq	uinoli	ne	A&D treatment				Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
Gerding 1993	6.75	3.9	41	7.25	4.8	28	100.0%	-0.50 [-2.64, 1.64]				
Total (95% CI)	nlianhla		41			28	100.0%	-0.50 [-2.64, 1.64]				
Heterogeneity: Not ap Test for overall effect:		(P = 0).65)						-4 -2 0 2 4 Favours oxyquinoline Favours A&D treatment			

Figure 421: Oxyquinoline versus A&D treatment – mean days to complete healing (grade II)

	Oxyquinoline			A&D t	reatm	ent		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Gerding 1993	7.8	4.47	45	13	3.94	23	100.0%	-5.20 [-7.27, -3.13]	-
Total (95% CI)			45			23	100.0%	-5.20 [-7.27, -3.13]	•
Heterogeneity: Not ap Test for overall effect:			0.00001)					-10 -5 0 5 10 Favours oxyquinoline Favours A&D treatment

I.2.7.14 Ethoxy-diaminoacridine plus nitrofuazone versus honey

Figure 422: Ethoxy-diaminoacridine plus nitrofuazone versus honey – proportion of ulcers completely healed

-	Ethoxy-diaminoac	ridine	Hone	ey		Peto Odds Ratio	Peto Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixe	ed, 95% CI	
Günes 2007	0	25	5	25	100.0%	0.11 [0.02, 0.71]			
Total (95% CI)		25		25	100.0%	0.11 [0.02, 0.71]			
Total events	0		5						
Heterogeneity: Not as Test for overall effect:	•						0.01 0.1	10 100	
restroi overali ellect.	Z = 2.33 (P = 0.02)						Favours honey	Favours ethoxy	

Figure 423: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mean percentage reduction in PUSH score

	Ethoxy-diaminoacridine			1	Honey			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Günes 2007	12.9	28.92	25	56.3	28.92	25	100.0%	-43.40 [-59.43, -27.37]	-
Total (95% CI) Heterogeneity: Not ap Test for overall effect:		< 0.00001)	25			25	100.0%	-43.40 [-59.43, -27.37]	-100 -50 0 50 100 Favours honey Favours ethoxy

Figure 424: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mean percentage reduction in ulcer size

	Ethoxy-diaminoacridine			ne Honey				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed	, 95% CI	
Günes 2007	13	29.39	25	56	29.39	25	100.0%	-43.00 [-59.29, -26.71]	-		
Total (95% CI)			25			25	100.0%	-43.00 [-59.29, -26.71]	•		
Heterogeneity: Not ap Test for overall effect:		< 0.00001))						-100 -50 (50 100 Favours ethoxy	

Figure 425: Ethoxy-diaminoacridine plus nitrofuazone versus honey – proportion of people with treatment-related adverse events

	Ethoxy-diaminoa	cridine	Hone	ey .		Peto Odds Ratio		Peto	Ode	ds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto,	Fixe	ed, 95% CI		
Günes 2007	0	11	0	15		Not estimable						
Total (95% CI)		11		15		Not estimable						
Total events	0		0									
Heterogeneity: Not app							0.01	0.1	 	10	10	
Test for overall effect:	Not applicable							urs etho	xyl	Favours h	oney	y

Figure 426: Ethoxy-diaminoacridine plus nitrofuazone versus honey – mortality

	Ethoxy-diaminoad	ridine	Hone	y		Peto Odds Ratio	Peto Od	ds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI	
Günes 2007	1	12	0	15	100.0%	9.49 [0.18, 489.97]			→
Total (95% CI)		12		15	100.0%	9.49 [0.18, 489.97]			
Total events	1		0						
Heterogeneity: Not ap Test for overall effect:	•					-	0.01 0.1 urs ethoxy-diamino	1 10 Favours hone	100 ey

I.2.7.15 Povidone-iodine versus hydrocolloid


Figure 427: Povidone-iodine versus hydrocolloid – proportion of patients completely healed


Povidone-iodine			Hydroco	olloid		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI	
Kim 1996	14	18	21	26	100.0%	0.96 [0.71, 1.31]	_	-	
Total (95% CI)		18		26	100.0%	0.96 [0.71, 1.31]		>	
Total events	14		21						
Heterogeneity: Not ap	plicable						0.2 0.5	1 1	
Test for overall effect:	Z = 0.24 (P =	0.81)					Favours hydrocolloid	Favours povidone-iodine	

Figure 428: Povidone-iodine versus hydrocolloid – mean speed of healing (mm²/day)

	Povido	ne-iod	line	Hydr	ocollo	oid		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Kim 1996	7.9	4.7	18	9.1	5.4	26	100.0%	-1.20 [-4.20, 1.80]	
Total (95% CI)			18			26	100.0%	-1.20 [-4.20, 1.80]	
Heterogeneity: Not a Test for overall effect		P = 0.	43)						-4 -2 0 2 4 Favours hydrocolloid Favours povidone-iodine

Figure 429: Povidone-iodine versus hydrocolloid – proportion of patients with hypergranulation





	Povidone-i	odine	Hydroco	olloid		Peto Odds Ratio		Peto Oc	lds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% C	1	
Kim 1996	0	18	0	26		Not estimable					
Total (95% CI)		18		26		Not estimable					
Total events	0		0								
Heterogeneity: Not appress for overall effect:		Э					0.01 0 Favours		1 1 Favours	0 hydr	100 ocolloid

I.2.7.16 Povideon-iodine vs. hydrogel

Figure 431: Povidone-iodine versus hydrogel – mean cm²/day to healing

	Povide	one-iod	ine	Hy	drogel	I		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Kaya 2005	0.09	0.05	24	0.12	0.16	25	100.0%	-0.03 [-0.10, 0.04]	-
Total (95% CI)			24			25	100.0%	-0.03 [-0.10, 0.04]	
Heterogeneity: Not ap Test for overall effect:			37)						-0.2 -0.1 0 0.1 0.2 Favours hydrogel Favours povidone-iodin

1.2.7.17 Cadexomer iodine vs. standard treatment

Figure 432: Cadexomer iodine versus standard treatment – proportion of ulcers reduced > 50%

	Cadexomer i	odine	Standard trea	tment		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI
Moberg 1983	8	16	1	18	100.0%	9.00 [1.26, 64.33]		
Total (95% CI)		16		18	100.0%	9.00 [1.26, 64.33]		
Total events	8		1					
Heterogeneity: Not ap	plicable						0.01 0.1	10 100
Test for overall effect:	Z = 2.19 (P = 0	.03)						Favour cadexomer iodine

Figure 433: Cadexomer iodine versus standard treatment – mean percentage reduction in ulcer area

	Cadexo	mer loc	tine	Standa	rd treatn	nent		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Moberg 1983	30.9	46	16	19.6	83.16	18	100.0%	11.30 [-33.24, 55.84]	
Total (95% CI)			16			18	100.0%	11.30 [-33.24, 55.84]	
Heterogeneity: Not ap Test for overall effect:		P = 0.62)						-100 -50 0 50 100 Favour standard treatment Favour cadexomer jodine

Figure 434: Cadexomer iodine versus standard treatment – mean cm² reduction in ulcer area

	Cadexo	mer io	dine	Standar	rd treatr	nent		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Moberg 1983	2.9	5.2	16	2.5	4.67	18	100.0%	0.40 [-2.94, 3.74]	
Total (95% CI)			16			18	100.0%	0.40 [-2.94, 3.74]	
Heterogeneity: Not ap Test for overall effect:		P = 0.81	1)						-10 -5 0 5 10 Favour standard treatment Favour cadexomer iodine

Figure 435: Cadexomer iodine versus standard treatment – mortality

0							,
	Cadexomer	iodine	Standard trea	atment		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	I Peto, Fixed, 95% CI
Moberg 1983	0	19	0	19		Not estimable	
Total (95% CI)		19		19		Not estimable	
Total events	0		0				
Heterogeneity: Not ap Test for overall effect:	•						0.01 0.1 1 10 100 Favours cadexomer Favours standard tmt

1.2.7.18 Silver sulfazidine cream vs. silver dressing

Figure 436: Silver sulfazidine cream versus silver dressing – mean percentage reduction in ulcer area

	(Cream		Dr	ressing			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Chuangsuwanich 2011	25.06	56.13	20	36.95	56.13	20	100.0%	-11.89 [-46.68, 22.90]	-
Total (95% CI) Heterogeneity: Not applica			20			20	100.0%	-11.89 [-46.68, 22.90]	-100 -50 0 50 100
Test for overall effect: $Z = 0$	0.67 (P =	0.50)							Favours cream Favours dressing

Figure 437: Silver sulfazidine cream versus silver dressing – proportion of people with treatment-related adverse events

	Crea	m	Dressi	ng		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ked, 95% CI	
Chuangsuwanich 2011	0	20	0	20		Not estimable				
Total (95% CI)		20		20		Not estimable				
Total events	0		0							
Heterogeneity: Not applie	cable						0.01		+ +	100
Test for overall effect: No	t applicab	le						0.1 vours cream	1 10 Favours dr	

Figure 438: Silver sulfazidine cream versus silver dressing – mortality

	Crear	n	Dressi	ing		Peto Odds Ratio	Peto Od	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI	
Chuansuwanich 2011	0	17	0	17		Not estimable			
Total (95% CI)		17		17		Not estimable			
Total events	0		0						
Heterogeneity: Not appl							0.01 0.1	 1 10	100
Test for overall effect: N	ot applical	oie					Favours cream	Favours dres	ssing

I.2.7.19 Resin salve vs. hydrofibre

Figure 439: Resin salve versus hydrofibre – proportion of patients completely healed



Figure 440: Resin salve versus hydrofibre – proportion of ulcers completely healed




Figure 441: Resin salve versus hydrofibre – proportion of ulcers improved

	Resin s	alve	Hydrof	ibre		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Sipponen 2008	18	18	10	11	100.0%	1.11 [0.89, 1.40]	_
Total (95% CI)		18		11	100.0%	1.11 [0.89, 1.40]	-
Total events	18		10				
Heterogeneity: Not as	oplicable						05 07 1 15 3
Test for overall effect:	Z = 0.93 (P = 0.3	5)				Favours hydrofibre Favours resin salve

Figure 442: Resin salve versus hydrofibre – proportion of ulcers worsened

	Resin s	alve	Hydrof	ibre		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Sipponen 2008	0	18	1	11	100.0%	0.07 [0.00, 4.07]	—
Total (95% CI)		18		11	100.0%	0.07 [0.00, 4.07]	
Total events	0		1				
Heterogeneity: Not as	plicable						0.005 0.1 1 10 200
Test for overall effect	Z = 1.28 (P = 0.2	0)				Favours resin salve Favours hydrofibre

Figure 443: Resin salve versus hydrofibre – proportion of patients with allergic skin reactions

	Resin salve Hydrot		ibre		Peto Odds Ratio	Peto Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Sipponen 2008	1	21	0	16	100.0%	5.82 [0.11, 304.33]	
Total (95% CI)		21		16	100.0%	5.82 [0.11, 304.33]	
Total events	1		0				
Heterogeneity: Not ap	plicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 0.87 (P = 0.3	8)			Favours resin salve Favours hydrocolloid	

Figure 444: Resin salve versus hydrofibre – mortality

	Resin s	alve	Hydrof	ibre		Risk Ratio			Risk Rat	io	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	i I	М-Н	Fixed, 9	95% CI	
Sipponen 2008	3	21	4	16	100.0%	0.57 [0.15, 2.20]		_			
Total (95% CI)		21		16	100.0%	0.57 [0.15, 2.20]		•			
Total events	3		4								
Heterogeneity: Not ap	plicable						0.01	0.1	+	10	100
Test for overall effect: $Z = 0.81$ (P = 0.42)								rs resin sa	alve Fa	vours hyd	

1.2.7.20 Antibiotic ointment vs. foam dressing

Figure 445: Antibiotic ointment versus foam dressing – proportion of patients completely healed

	Antibio	otic	Foar	n		Risk Ratio			Ris	k R	atio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-	·H, Fix	ked	, 95%	CI		
Yastrub 2004	15	23	18	21	100.0%	0.76 [0.54, 1.08]			-	-				
Total (95% CI)		23		21	100.0%	0.76 [0.54, 1.08]			⋖					
Total events	15		18											
Heterogeneity: Not app Test for overall effect:		P = 0.12	2)				0.1	0.2 Favours	0.5 foam	1 1	2 avours	5 s ant	1 ibio	-

I.2.7.21 Insulin vs. standard treatment

Figure 446: Insulin versus standard treatment - mortality

	Insuli	in	Placel	bo		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Van Ort 1976	0	6	0	8		Not estimable		
Total (95% CI)		6		8		Not estimable		
Total events	0		0					
Heterogeneity: Not app Test for overall effect:		able					0.01 0.1 1 10 1 Favours insulin Favours placel	00 bo

I.2.7.22 Growth factors vs. placebo

Figure 447: Growth factors versus placebo – proportion of patients completely healed

Growth	Iacto	is vers	us pi	acebo	– proportion of p	datients completely healed
Experim					Risk Ratio	Risk Ratio
Events		Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
rsus placel	00					
1	9	0	5 5	12.5% 12.5%	1.80 [0.09, 37.49] 1.80 [0.09, 37.49]	
1		0				
pplicable						
t: Z = 0.38 (F	P = 0.70)				
•						
8	18 18	1	18 18	18.1% 18.1%	8.00 [1.11, 57.57] 8.00 [1.11, 57.57]	
8		1				
-						
	0.04)				
rsus placeb	10					
2	30	1	14	16.1%	0.93 [0.09, 9.45]	
14	93	0	31	13.6%	9.87 [0.61, 160.81]	
2	13	0	7	13.0%	2.86 [0.16, 52.42]	-
	136		52	42.8%	2.55 [0.56, 11.65]	→
18		1				
		-	= 0.39	$ 1^2 = 0\% $		
t: Z = 1.21 (F	P = 0.23)				
ersus place	bo					
27	41	10	13	26.6%	0.86 [0.59, 1.24]	†
	41		13	26.6%	0.86 [0.59, 1.24]	•
		10				
t: Z = 0.82 (F	9 = 0.41)				
0		0				
	18		6		Not estimable	
-		U				
	oblo					
t. Not applic	able					
	222		94	100.0%	2.33 [0.54, 10.02]	-
54		12				
			P = 0.0	05); I² = 7	0%	0.002 0.1 1 10 500
						Favours control Favours experimenta
fferences: C	$hi^2 = 6.$	53. df = 3	(P = 0	.09). $I^2 = 6$	54.1%	The state of the s
	Experime Events risus placet 1 applicable t: Z = 0.38 (F s placebo 8 applicable t: Z = 2.07 (F risus placeb 2 14 2 18 = 0.00; Chi ^a t: Z = 1.21 (F ersus place 27 applicable t: Z = 0.82 (F ersus place t: Z = 0.82 (F ersus placeb 0 applicable t: Not applic t: Not applic t: Z = 1.14 (F ersus placeb 1 applicable t: Not applic t: Z = 1.14 (F ersus placeb 1 applicable t: Not applic t: Z = 1.14 (F ersus placeb 1 applicable t: Not applic t: Z = 1.14 (F ersus placeb 1 applicable t: Not applic t: Z = 1.14 (F	Experimental Events Total (argus placebo 1 9 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Experimental Contributes Total Events Total Eve	Experimental Control Events Total Events Total resus placebo 1 9 0 5 9 5 1 0 pplicable t: Z = 0.38 (P = 0.70) s placebo 8 18 1 18 8 1 spplicable t: Z = 2.07 (P = 0.04) resus placebo 2 30 1 14 14 93 0 31 2 13 0 7 136 52 18 1	Experimental Events Total Weight From Process Total Forms Total Forms Total Weight From Process Total Forms Total Forms Process Total Forms Total Forms Total Forms Process Total Forms To	Events Total Events Total Weight M-H, Random, 95% CI strust placebo 1 9 0 5 12.5% 1.80 [0.09, 37.49] 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Figure 448: Proportion of patients completely healed – growth factors versus placebo – inpatients – grade 3 and 4

		0					
	Growth fa	actor	Placebo			Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total 8	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
38.1.1 TGF-beta3 ver	sus placeb	ю					
Hirshberg 2003 Subtotal (95% CI)	1	9	0	5	3.0% 3.0%	4.74 [0.08, 283.15] 4.74 [0.08, 283.15]	
Total events	1		0				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.75 (P	= 0.46)					

Figure 449: Proportion of patients completely healed – growth factors versus placebo – nursing home patients – grade 2 and above


0			- 0 -						
	NGF	=	Placel	bo		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fix	ed, 95% CI	
Landi 2003	8	18	1	18	100.0%	8.00 [1.11, 57.57]			
Total (95% CI)		18		18	100.0%	8.00 [1.11, 57.57]		~	
Total events	8		1						
Heterogeneity: Not app Test for overall effect: 2		o = 0.0	4)				0.002 0.1 Favours placebo	H 10 Favours N	500

1.2.7.23 Topical growth factor – beta 3: 1.0ug/cm² versus placebo

Figure 450: Topical growth factor – beta 3: 1.0ug/cm² versus placebo – proportion of people with pressure ulcers completely healed

-			•	•						
	TGF-beta 3 (1.0) placebo			Peto Odds Ratio		Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Hirshberg 2003	0	4	0	5		Not estimable				
Total (95% CI)		4		5		Not estimable				
Total events	0		0							
Heterogeneity: Not ap	•						0.01	0.1	1 1	0 100
Test for overall effect:	Э					Fa	vours placebo	Favours T	GF-beta 3 (1.	

Figure 451: Topical growth factor – beta 3: 1.0ug/cm² versus placebo – mortality



1.2.7.24 Topical growth factor – beta 3: 2.5ug/cm² versus placebo

Figure 452: Topical growth factor – beta 3: 2.5ug/cm2 versus placebo

	TGF 2	2.5	Placel	bo		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Hirshberg 2003	1	5	0	5	100.0%	7.39 [0.15, 372.38]	
Total (95% CI)		5		5	100.0%	7.39 [0.15, 372.38]	
Total events	1		0				
Heterogeneity: Not app	olicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 1.00 (I	P = 0.33	2)				Favours placebo Favours TGF 2.5

Figure 453: Topical growth factor – beta 3: 2.5ug/cm2 versus placebo

		TGF 2	2.5	Place	bo		Peto Odds Ratio	Peto Odds Ratio
Study or S	ubgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Hirshberg 2	003	0	5	1	4	100.0%	0.11 [0.00, 5.44]	
Total (95%	CI)		5		4	100.0%	0.11 [0.00, 5.44]	
Total events	S	0		1				
Heterogene	ity: Not applic	cable						
Test for ove	erall effect: Z	= 1.12 (I	P = 0.26	6)				0.01 0.1 1 10 100 Favours TGF 2.5 Favours placebo

1.2.7.25 Topical growth factor – beta 3: 1.02g/cm² versus 2.52g/cm²

Figure 454: Topical growth factor – beta 3: 1.02g/cm² versus 2.52g/cm² – proportion of patients completely healed




Figure 455: Topical growth factor – beta 3: 1.02g/cm² versus 2.52g/cm² – mortality

	TGF-beta	3 (1.0)	TGF-beta	3 (2.5)		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Hirshberg 2003	1	4	0	5	100.0%	9.49 [0.18, 489.97]	
Total (95% CI)		4		5	100.0%	9.49 [0.18, 489.97]	
Total events	1		0				
Heterogeneity: Not ap Test for overall effect:	•	0.26)					0.01 0.1 1 10 100 Favours TGF-beta 3 (1.0) Favours TGF-beta 3 (2.5)

1.2.7.26 Nerve growth factor (2.5 S murine) versus placebo

Figure 456: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients completely healed (foot ulcers)

·	NGF		Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Landi 2003	8	18	1	18	100.0%	8.00 [1.11, 57.57]	
Total (95% CI)		18		18	100.0%	8.00 [1.11, 57.57]	-
Total events	8		1				
Heterogeneity: Not ap	plicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 2.07 ((P = 0.0)	14)				Favours placebo Favours NGF

Figure 457: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients improved by 3 or more grades (foot ulcers)

	NGF	NGF Placebo		bo		Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI			
Landi 2003	5	18	0	18	100.0%	9.56 [1.48, 61.61]				
Total (95% CI)		18		18	100.0%	9.56 [1.48, 61.61]	-			
Total events	5		0							
Heterogeneity: Not ap	plicable						0.001 0.1 1 10 1000			
Test for overall effect:	Z = 2.38 ((P = 0.0)	12)				Favours placebo Favours NGF			

Figure 458: Nerve growth factor (2.5 S murine) versus placebo – proportion of patients improved by 2 grades (foot ulcers)

•	•	_	•		•		
	NGF		Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Landi 2003	14	18	2	18	100.0%	7.00 [1.85, 26.46]	-
Total (95% CI)		18		18	100.0%	7.00 [1.85, 26.46]	•
Total events	14		2				
Heterogeneity: Not ap	plicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 2.87	(P = 0.0)	004)				Favours placebo Favours NGF

Figure 459: Nerve growth factor (2.5 S murin) versus placebo – proportion of patients improved by 1 grade (foot ulcers)

	NGF		Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Landi 2003	18	18	8	18	100.0%	2.18 [1.31, 3.61]	-
Total (95% CI)		18		18	100.0%	2.18 [1.31, 3.61]	•
Total events	18		8				
Heterogeneity: Not ag	plicable						0.05 0.2 1 5 20
Test for overall effect:	Z = 3.02	(P = 0.0)	03)				Favours placebo Favours NGF

Figure 460: Nerve growth factor (2.5 S murin) versus placebo – mean mm² reduction in ulcer area (foot ulcers)

		NGF		Pla	acebo)		Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Landi 2003	738	393	18	485	384	18	100.0%	253.00 [-0.83, 506.83]			
Total (95% CI)			18			18	100.0%	253.00 [-0.83, 506.83]	•		
Heterogeneity: Not as Test for overall effect:			0.05)						-1000 -500 0 500 1000 Favours placebo Favours NGF		

Figure 461: Nerve growth factor (2.5 S murin) versus placebo – mean mm2 reduction in ulcer area (foot ulcers) – grade 2 and above




Figure 462: Nerve growth factor (2.5 S murin) versus placebo – proportion of people with treatment-related adverse events

	NGF	Place	bo		Peto Odds Ratio	Peto Od	lds Ratio
Study or Subgroup	Events Total	al Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI
Landi 2003	0 1	8 0	18		Not estimable		
Total (95% CI)	1	8	18		Not estimable		
Total events	0	0					
Heterogeneity: Not app Test for overall effect: I						0.01 0.1 Favours NGF	1 10 100 Favours placebo

Figure 463: Nerve growth factor (2.5 S murin) versus placebo – mortality

	NGF	=	Placel	bo		Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI				
Landi 2003	1	19	0	19	100.0%	7.39 [0.15, 372.38]					
Total (95% CI)		19		19	100.0%	7.39 [0.15, 372.38]					
Total events	1		0								
Heterogeneity: Not ap Test for overall effect:	•	P = 0.3	2)				0.01 0.1 1 10 100 Favours mNGF Favours placebo				

1.2.7.27 Recombinant platelet-derived growth factor (1002g/ml) versus placebo

Figure 464: Recombinant platelet-derived growth factor (100@g/ml) versus placebo – proportion of patients completely healed

	PDGF-BB	100	Place	bo		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Mustoe 1994	6	16	2	14	77.0%	2.63 [0.63, 10.98]	+-			
Robson 1992b	2	13	0	7	23.0%	2.86 [0.16, 52.42]	-			
Total (95% CI)		29		21	100.0%	2.68 [0.74, 9.74]	-			
Total events	8		2							
Heterogeneity: Chi2=	0.00, df = 1	(P = 0.	.96); l² = 1	0%			0.01 0.1 1 10 100			
Test for overall effect:	6 16 2 13 29 8 0.00, df = 1 (P = 0.9)				Favoursplacebo Favours PDGF-BB 100			

Figure 465: Recombinant platelet-derived growth factor (100 g/ml) versus placebo – mortality

	PDGF-B	B 100	Placel	00		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Robson 1992b	0	35	0	15		Not estimable	
Total (95% CI)		35		15		Not estimable	•
Total events	0		0				
Heterogeneity: Not app Test for overall effect:		ble					0.01 0.1 1 10 100 Favours rPDGF-BB Favours placebo


I.2.7.28 Recombinant platelet-derived growth factor: 100 g/ml versus 300 g/ml

Figure 466: Recombinant platelet-derived growth factor: 1002g/ml versus 3002g/ml – proportion of patients completely healed

	PDGF-BB	100	PDGF-BB	300		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Mustoe 1994	6	16	3	12	100.0%	1.50 [0.47, 4.82]	_			
Total (95% CI)		16		12	100.0%	1.50 [0.47, 4.82]	-			
Total events	6		3							
Heterogeneity: Not as	plicable						0.01 0.1 1 10 100			
Test for overall effect	Z = 0.68 (P	= 0.50)				Favours PDGF-BB 300 Favours PDGF-BB 100			

I.2.7.29 Recombinant platelet-derived growth factor (3002g/ml) versus placebo

Figure 467: Recombinant platelet-derived growth factor (300½g/ml) versus placebo – proportion of patients completely healed



1.2.7.30 Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus placebo

Figure 468: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus placebo – proportion of patients completely healed (after 1 year)




Figure 469: Granulo-macrophage/colony-stimulating factor (2.0⊡g/cm²) versus placebo – proportion of patients worsened (after 1 year)

	GM-C	SF	Place	bo		Peto Odds Ratio	Peto Odds Ratio				
Study or Subgroup	Events	Total	14 0 13	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI					
Payne 2001	2	14	0	13	100.0%	7.43 [0.44, 125.76]					
Total (95% CI)		14		13	100.0%	7.43 [0.44, 125.76]					
Total events	2		0								
Heterogeneity: Not as	oplicable						0.002 0.1 1 10 500				
Test for overall effect:	Z = 1.39	(P = 0.1)	6)				Favours GM-CSF Favours placebo				

Figure 470: Granulo-macrophage/colony-stimulating factor (2.0⊡g/cm²) versus placebo – mean percentage reduction in ulcer area

	GM	I-CSI	F	Pla	cebo)		Mean Difference	Mean Difference
Study or Subgrou	p Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Robson 2000	67	24	15	71	11	15	100.0%	-4.00 [-17.36, 9.36]	-
Total (95% CI)			15			15	100.0%	-4.00 [-17.36, 9.36]	-
Heterogeneity: No Test for overall eff			0.56)						-50 -25 0 25 50 Favours placebo Favours GM-CSF

Figure 471: Granulo-macrophage/colony-stimulating factor (2.0⊡g/cm²) versus placebo –

	GM-C	GM-CSF Placebo				Peto Odds Ratio			Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I	Peto,	Fixed, 9	5% CI		
Robson 2000	0	15	0	15		Not estimable						
Total (95% CI)		15		15		Not estimable						
Total events	0		0									
Heterogeneity: Not applicable Test for overall effect: Not applicable						F	0.01 avours r	0.1 GM-CSF 2	1 2.0 Fav	10 ours plac	100 ebo	

I.2.7.31 Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus basic fibroblast growth factor (5.0½g/cm²)

Figure 472: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus basic fibroblast growth factor (5.02g/cm²) – proportion of patients completely healed (after 1 year)

	GM-CSF		BFG	BFGF		Risk Ratio	Risk Ratio
Study or Subgroup	Events Total Events		Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Payne 2001	8	14	10	14	100.0%	0.80 [0.46, 1.40]	-
Total (95% CI)		14		14	100.0%	0.80 [0.46, 1.40]	*
Total events	8		10				
Heterogeneity: Not ag	plicable						01 02 05 1 2 5 10
Test for overall effect:	Z = 0.78	(P = 0.4)	4)				Favours BFGF Favours GM-CSF

Figure 473: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus basic fibroblast growth factor (5.02g/cm²) – proportion of patients worsened (after 1 year)

	GM-CSF		BFG	F		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI		
Payne 2001	2	14	4	14	100.0%	0.50 [0.11, 2.30]	-		
Total (95% CI)		14		14	100.0%	0.50 [0.11, 2.30]	-		
Total events	2		4						
Heterogeneity: Not as	plicable						0.002 0.1 1 10 500		
Test for overall effect:	Z = 0.89	(P = 0.3)	17)				Favours GM-CSF Favours BFGF		

Figure 474: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) versus basic fibroblast growth factor (5.02g/cm²) – mean percentage reduction in ulcer area

	GM-CSF BFGF						Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
Robson 2000	67	24	15	75	19	15	100.0%	-8.00 [-23.49, 7.49]	-	
Total (95% CI) Heterogeneity: Not as	nnlicable		15			15	100.0%	-8.00 [-23.49, 7.49]	•	
Test for overall effect			0.31)						-100 -50 0 50 100 Favours BFGF Favours GM-CSF	

Figure 475: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus basic fibroblast growth factor (5.0½g/cm²) – mortality

		•	U		•		
	GM-CSF		BFGF			Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Robson 2000	0	15	0	15		Not estimable	
Total (95% CI)		15		15		Not estimable	
Total events	0		0				
Heterogeneity: Not ap	. 1. 1.					0.01 0.1 1 10 100	
Test for overall effect:	able					Favours rGM-CSF 2.0 Favours rBFGF 5.0	

I.2.7.32 Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²)

Figure 476: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – proportion of patients completely healed (after 1 year)

	GM-CSF GM-CSF/BFGF					Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI		
Payne 2001	8	14	9	13	100.0%	0.83 [0.46, 1.48]	-		
Total (95% CI)		14		13	100.0%	0.83 [0.46, 1.48]	•		
Total events	8		9						
Heterogeneity: Not ap	plicable						0.05 0.2 1 5 20		
Test for overall effect:	Z = 0.65 ((P = 0.5)	52)			F	avours GM-CSF/BFGF Favours GM-CSF		

Figure 477: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – proportion of patients worsened (after 1 year)

	GM-CSF GM-CSF/BFGF			/BFGF		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI		
Payne 2001	2	14	1	13	100.0%	1.86 [0.19, 18.13]	_			
Total (95% CI)		14		13	100.0%	1.86 [0.19, 18.13]				
Total events	2		1							
Heterogeneity: Not ap	plicable						0.001 0.1	10	1000	
Test for overall effect:	Z = 0.53	(P = 0.5)	59)				Favours GM-CSF	Favours		

Figure 478: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – mean percentage reduction in ulcer area

	GM-CSF/BFGF				GF		Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Robson 2000	67	24	15	68	21	16	100.0%	-1.00 [-16.92, 14.92]	
Total (95% CI)			15			16	100.0%	-1.00 [-16.92, 14.92]	+
Heterogeneity: Not applicable Test for overall effect: Z = 0.12 (P = 0.90)									-100 -50 0 50 100 Favours GM-CSF/BFGF Favours GM-CSF

Figure 479: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – mortality

	GM-C	SF	GM-CSF/BFGF		Peto Odds Ratio	atio Peto Oc		dds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fi	xed, 95% CI	
Robson 2000	0	15	0	16		Not estimable				
Total (95% CI)		15		16		Not estimable				
Total events	0		0							
Heterogeneity: Not app	plicable						0.01	0.1	1	10 100
Test for overall effect:	Not applic	able						•	-	GM-CSF/rBFGF

1.2.7.33 Basic fibroblast growth factor (5.02g/cm²) versus placebo

Figure 480: Basic fibroblast growth factor (5.0½g/cm²) versus placebo – proportion of patients completely healed (after 1 year)

	BFG	Place	bo		Risk Ratio	Risk Ratio			
Study or Subgroup	Events Total Events To		Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Payne 2001	10	14	10	13	100.0%	0.93 [0.59, 1.45]	-		
Total (95% CI)		14		13	100.0%	0.93 [0.59, 1.45]	-		
Total events	10		10						
Heterogeneity: Not ag	plicable						03 05 1 3 5		
Test for overall effect:	Z = 0.33	(P = 0.7)	(4)				Favours placebo Favours BFGF		

Figure 481: Basic fibroblast growth factor (5.0½g/cm²) versus placebo – proportion of patients worsened (after 1 year)

	BFG	F	Place	bo		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Payne 2001	4	14	0	13	100.0%	8.85 [1.10, 71.20]	
Total (95% CI)		14		13	100.0%	8.85 [1.10, 71.20]	-
Total events	4		0				
Heterogeneity: Not ap							0.002 0.1 1 10 500
Test for overall effect:	Z = 2.05	(P = 0.0)	04)				Favours BGFG Favours placebo

Figure 482: Basic fibroblast growth factor (5.02g/cm²) versus placebo – mean percentage reduction in ulcer area

	BFGF			Placebo				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
Robson 2000	75	19	15	71	11	15	100.0%	4.00 [-7.11, 15.11]	_		
Total (95% CI)			15			15	100.0%	4.00 [-7.11, 15.11]	•		
Heterogeneity: Not as Test for overall effect			0.48)						-20-10 0 10 20 Favours placebo Favours BGFG		

Figure 483: Basic fibroblast growth factor (5.02g/cm²) versus placebo – mortality

	BFGF		Place	bo		Peto Odds Ratio	Peto Od	ds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fix	ed, 95% CI	
Robson 2000	0	15	0	15		Not estimable			
Total (95% CI)		15		15		Not estimable			
Total events	0		0						
Heterogeneity: Not app	olicable						0.01 0.1	 	100
Test for overall effect:	Not applic	able					Favours rBFGF		

I.2.7.34 Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²)

Figure 484: Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – proportion of patients completely healed (after 1 year)

	BFG	GM-CSF/	BFGF		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Payne 2001	10	14	9	13	100.0%	1.03 [0.63, 1.69]	-
Total (95% CI)		14		13	100.0%	1.03 [0.63, 1.69]	*
Total events	10		9				
Heterogeneity: Not as	plicable						0.1 0.2 0.5 1 2 5 10
Test for overall effect:	overall effect: Z = 0.12 (P = 0.90)					Fa	vours GM-CSF/BFGF Favours BFGF

Figure 485: Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – proportion of patients worsened (after 1 year)




Figure 486: Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – mean percentage reduction in ulcer area




Figure 487: Basic fibroblast growth factor (5.0½g/cm²) versus granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) – mortality

	BFG	F	GM-CSF/BFGF			Peto Odds Ratio		Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl		Peto, Fix	ed, 95% C	1	
Robson 2000	0	15	0	16		Not estimable					
Total (95% CI)		15		16		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:		able					0.01 Fav	0.1 ours rBFGF 5.0	1 Favours	10 rGM-(100 CSF/rBFG

I.2.7.35 Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) versus placebo

Figure 488: Granulo-macrophage/colony-stimulating factor (2.02g/cm²) and basic fibroblast growth factor (5.02g/cm²) versus placebo – proportion of patients completely healed (after 1 year)

-	GM-CSF/	BFGF	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Payne 2001	9	13	10	13	100.0%	0.90 [0.56, 1.44]	-
Total (95% CI)		13		13	100.0%	0.90 [0.56, 1.44]	•
Total events	9		10				
Heterogeneity: Not as Test for overall effect		0 = 0 66					0.1 0.2 0.5 1 2 5 10
restion overall effect	. 2 = 0.44 (1	- 0.00	,				Favours placebo Favours GM-CSF/BFGF

Figure 489: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) versus placebo – proportion of patients worsened (after 1 year)

, ,							
	GM-CSF/	BFGF	Place	cebo		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	Peto, Fixed, 95% CI
Payne 2001	1	13	0	13	100.0%	7.39 [0.15, 372.38	
Total (95% CI)		13		13	100.0%	7.39 [0.15, 372.38]	
Total events	1		0				
Heterogeneity: Not ap	plicable						0.001 0.1 1 10 1000
Test for overall effect:	Z = 1.00 (F	P = 0.32)				Favours GM-CSF/BFGF Favours placebo

Figure 490: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) versus placebo – mean percentage reduction in ulcer area




Figure 491: Granulo-macrophage/colony-stimulating factor (2.0½g/cm²) and basic fibroblast growth factor (5.0½g/cm²) versus placebo – mortality

	GM-CSF	BFGF	Placel	bo	Peto Odds Ratio		Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight Peto, Fixed, 95% CI		Peto, Fixed, 95% CI
Robson 2000	0	16	0	15		Not estimable	
Total (95% CI)		16		15		Not estimable	
Total events	0		0				
Heterogeneity: Not app Test for overall effect:		ole				Favo	0.01 0.1 1 10 100 burs rGM-CSF/rBFGF Favours placebo

1.2.7.36 Recombinant platelet-derived growth factor (100½g/g) versus placebo

Figure 492: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients completely healed

	PDGF-BB	PDGF-BB 100 Placebo			Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fix	ed, 95% CI	
Rees 1999	7	31	0	31	100.0%	9.19 [1.93, 43.75]			
Total (95% CI)		31		31	100.0%	9.19 [1.93, 43.75]		-	
Total events	7		0						
Heterogeneity: Not ap	plicable						0.005 0.1	1 10 200	
Test for overall effect:	Z = 2.79 (F	0.00	5)					Favours PDGF-BB 100	

Figure 493: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients ≥ 90% healed

	PDGF-BB	100	Placebo			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	18	31	9	31	100.0%	2.00 [1.07, 3.74]	-
Total (95% CI)		31		31	100.0%	2.00 [1.07, 3.74]	•
Total events	18		9				
Heterogeneity: Not ap	plicable						0.05 0.2 1 5 20
Test for overall effect: Z = 2.17 (P = 0.03)							Favours placebo Favours PDGF-BB 100

Figure 494: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients with osteomyelitis

	PDGF-BB	PDGF-BB 100 Placebo		•	Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Rees 1999	2	31	1	31	100.0%	2.00 [0.19, 20.93]	
Total (95% CI)		31		31	100.0%	2.00 [0.19, 20.93]	
Total events	2		1				
Heterogeneity: Not ap	plicable						0.002 0.1 1 10 500
Test for overall effect:	Z = 0.58 (F	P = 0.56)				Favours PDGF-BB 100 Favours placebo

Figure 495: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients with an infection




Figure 496: Recombinant platelet-derived growth factor (100½g/g) versus placebo – proportion of patients with adverse events other than osteomyelitis, infection and sepsis

•	PDGF-BB	PDGF-BB 100 Placebo		bo		Risk Ratio	Risk	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI			
Rees 1999	2	31	2	31	100.0%	1.00 [0.15, 6.66]	_	_			
Total (95% CI)		31		31	100.0%	1.00 [0.15, 6.66]	-				
Total events	2		2								
Heterogeneity: Not as	plicable						0.001 0.1	10	1000		
Test for overall effect:	Test for overall effect: Z = 0.00 (P = 1.00)						Favours PDGF-BB 100				

Figure 497: Recombinant platelet-derived growth factor (100@g/g) versus placebo – mortality

	PDGF-BI	B 100	Placebo			Peto Odds Ratio		Peto Oc	lds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI		Peto, Fix	ed, 95% CI	
Rees 1999	0	31	0	31		Not estimable				
Total (95% CI)		31		31		Not estimable				
Total events	0		0							
Heterogeneity: Not appress for overall effect:	•	blo					0.01).1	1 10	100
rest for overall effect.					Favour	s rPDGF	Favours pla	acebo		

I.2.7.37 Recombinant platelet-derived growth factor: 100@g/g versus 300@g/g alternated with placebo

Figure 498: Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g alternated with placebo – proportion of patients completely healed

	PDGF-BB	100	PDGF-BB/placebo		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	7	31	6	32	100.0%	1.20 [0.46, 3.18]	
Total (95% CI)		31		32	100.0%	1.20 [0.46, 3.18]	*
Total events	7		6				
Heterogeneity: Not a	pplicable						0.01 0.1 1 10 100
Test for overall effect: Z = 0.37 (P = 0.71)							Favours PDGF-BB/placebo Favours PDGF-BB 100

Figure 499: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g alternated with placebo – proportion of patients ≥ 90% healed

	PDGF-BE	3 100	PDGF-BB/placebo			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	18	31	19	32	100.0%	0.98 [0.65, 1.48]	
Total (95% CI)		31		32	100.0%	0.98 [0.65, 1.48]	-
Total events	18		19				
Heterogeneity: Not applicable							02 06 1 3 6
Test for overall effect: Z = 0.11 (P = 0.92)							Favours PDGF-BB/placebo Favours PDGF-BB 100

Figure 500: Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g alternated with placebo – proportion of patients with osteomyelitis

	PDGF-BB	100	PDGF-BB/placebo			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	2	31	1	32	100.0%	2.06 [0.20, 21.63]	
Total (95% CI)		31		32	100.0%	2.06 [0.20, 21.63]	
Total events	2		1				
Heterogeneity: Not as						0.001 0.1 1 10 1000	
Test for overall effect	Z = 0.60 (F	P = 0.55)				Favours PDGF-BB 100 Favours PDGF-BB/placebo

Figure 501: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g alternated with placebo – infection

	PDGF-B	B 100	PDGF-BB/p	lacebo		Peto Odds Ratio		Peto Oc	lds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I	Peto, Fix	ed, 95% CI		
Rees 1999	0	31	0	32		Not estimable					
Total (95% CI)		31		32		Not estimable					
Total events Heterogeneity: Not ap	0 plicable		0					+			
Test for overall effect:	•	ble						0.1 DGF-BB 100	1 1 Favours rPI	-	100 3B 300

Figure 502: Recombinant platelet-derived growth factor: 100@g/g versus 300@g/g alternated with placebo – proportion of patients with sepsis

	PDGF-BB	100	PDGF-BB/placebo		Peto Odds Ratio		Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Rees 1999	0	31	1	32	100.0%	0.14 [0.00, 7.04]	
Total (95% CI)		31		32	100.0%	0.14 [0.00, 7.04]	
Total events	0		1				
Heterogeneity: Not applicable							0.002 0.1 1 10 500
Test for overall effect: Z = 0.98 (P = 0.32)							Favours PDGF-BB 100 Favours PDGF-BB/placebo

Figure 503: Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g alternated with placebo – Proportion of patients with adverse events other than osteomyelitis, infection and sepsis

	PDGF-BI	B 100	PDGF-BB/p	PDGF-BB/placebo		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI				
Rees 1999	2	31	3	32	100.0%	0.69 [0.12, 3.84]					
Total (95% CI)		31		32	100.0%	0.69 [0.12, 3.84]					
Total events	2		3								
Heterogeneity: Not app Test for overall effect:		= 0.67)									

Figure 504: Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g alternated with placebo – mortality

	PDGF-B	PDGF-BB 100		lacebo		Peto Odds Ratio		Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I	Peto, Fi	xed, 95% CI		
Rees 1999	0	31	0	32		Not estimable					
Total (95% CI)		31		32		Not estimable					
Total events	0		0								
Heterogeneity: Not ap Test for overall effect:	•	ıble					0.01 Favours	0.1 s rPDGF-BB 100	1 10 Favours rPD		100 3B 300

I.2.7.38 Recombinant platelet-derived growth factor: 100□g/g versus 300□g/g

Figure 505: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g – proportion of patients completely healed




Figure 506: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g – proportion of patients ≥ 90% healed

•	PDGF-BB 100		PDGF-BB 300		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	18	31	12	30	100.0%	1.45 [0.85, 2.47]	+
Total (95% CI)		31		30	100.0%	1.45 [0.85, 2.47]	-
Total events	18		12				
Heterogeneity: Not applicable							0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z = 1.38 (P = 0.17)							Favours PDGF-BB 300 Favours PDGF-BB 100

Figure 507: Recombinant platelet-derived growth factor: 100@g/g versus 300@g/g – proportion of patients with osteomyelitis

-	PDGF-BB	100	PDGF-BE	300		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Rees 1999	2	31	0	30	100.0%	7.40 [0.45, 121.11]	
Total (95% CI)		31		30	100.0%	7.40 [0.45, 121.11]	
Total events	2		0				
Heterogeneity: Not as					0.002 0.1 1 10 500		
Test for overall effect: Z = 1.40 (P = 0.16)							Favours PDGF-BB 100 Favours PDGF-BB 300

Figure 508: Recombinant platelet-derived growth factor: 1002g/g versus 3002g/g – proportion of patients with an infection

•							
	PDGF-BB	100	PDGF-BE	3 300		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Rees 1999	0	31	1	30	100.0%	0.13 [0.00, 6.60]	
Total (95% CI)		31		30	100.0%	0.13 [0.00, 6.60]	
Total events	0		1				
Heterogeneity: Not ap	plicable						0.001 0.1 1 10 1000
Test for overall effect:	Z = 1.02 (F	= 0.31)				Favours PDGF-BB 100 Favours PDGF-BB 300

Figure 509: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g – proportion of patients with adverse events other than osteomyelitis, infection and sepsis

	PDGF-BI	3 100	PDGF-B	B 300		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
Rees 1999	2	31	2	30	100.0%	0.97 [0.15, 6.44]	
Total (95% CI)		31		30	100.0%	0.97 [0.15, 6.44]	
Total events	2		2				
Heterogeneity: Not app Test for overall effect:		= 0.97)					0.01 0.1 1 10 100 Favours PDGF-BB 100 Favours PDGF-BB 300

Figure 510: Recombinant platelet-derived growth factor: 100½g/g versus 300½g/g − mortality

	PDGF-BI	B 100	PDGF-B	B 300		Peto Odds Ratio	Peto C	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	I Peto, Fi	xed, 95% CI	
Rees 1999	0	31	0	30		Not estimable			
Total (95% CI)		31		30		Not estimable			
Total events	0		0						
Heterogeneity: Not app	olicable						0.01 0.1	1 10	100
Test for overall effect: I	Not applica	ble					Favours rPDGF-BB 100		

1.2.7.39 Recombinant platelet-derived growth factor (3002g/g) alternated with placebo versus placebo

Figure 511: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients completely healed

	PDGF-BB/placebo		Placebo		Peto Odds Ratio		Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
Rees 1999	6	32	0	31	100.0%	8.51 [1.60, 45.18]	
Total (95% CI)		32		31	100.0%	8.51 [1.60, 45.18]	-
Total events	6		0				
Heterogeneity: Not ap							0.005 0.1 1 10 200
Test for overall effect:	Z = 2.51 (P = 0	1.01)					Favours placebo Favours PDGF-BB/place

Figure 512: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients ≥ 90% healed

	PDGF-BB/pla	PDGF-BB/placebo		Placebo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Rees 1999	19	32	9	31	100.0%	2.05 [1.10, 3.80]	
Total (95% CI)		32		31	100.0%	2.05 [1.10, 3.80]	•
Total events	19		9				
Heterogeneity: Not applicable							0.05 0.2 1 5 20
Test for overall effect: Z = 2.26 (P = 0.02)							Favours placebo Favours PDGF-BB/place

Figure 513: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients with osteomyelitis

	PDGF-BB/placebo		Placebo			Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI		
Rees 1999	2	31	1	31	100.0%	2.00 [0.19, 20.93]	_			
Total (95% CI)		31		31	100.0%	2.00 [0.19, 20.93]				
Total events	2		1							
Heterogeneity: Not as	plicable				0.002 0.1 1	10	500			
Test for overall effect:	Z = 0.58 (P = 0.58)	0.56)				Fav	ours PDGF-BB/placebo			

Figure 514: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients with an infection

	•	•	•							
	PDGF-BB/placebo		Place	bo		Peto Odds Ratio	Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixe	ed, 95% CI		
Rees 1999	0	32	1	31	100.0%	0.13 [0.00, 6.61]				
Total (95% CI)		32		31	100.0%	0.13 [0.00, 6.61]				
Total events	0		1							
Heterogeneity: Not ap	plicable						0.002 0.1	10	500	
Test for overall effect:	Z = 1.02 (P = 0)	1.31)				Fav	ours PDGF-BB/placebo	Favours place		

Figure 515: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients with sepsis

		-		-			
PDGF-BB/placebo			Place	bo		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fixed, 95% CI
Rees 1999	1	32	0	31	100.0%	7.16 [0.14, 361.11]	
Total (95% CI)		32		31	100.0%	7.16 [0.14, 361.11]	
Total events	1		0				
Heterogeneity: Not as						0.002 0.1 1 10 500	
Test for overall effect	0.32)				Fa	avours PDGF-BB/placebo Favours placebo	

Figure 516: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo – proportion of patients with adverse events other than osteomyelitis, infection and sepsis




Figure 517: Recombinant platelet-derived growth factor (300½g/g) alternated with placebo versus placebo − mortality

	PDGF-BB/placebo		Placel	bo	Peto Odds Ratio			Peto Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl		Peto, Fi	xed, 95% CI		
Rees 1999	0	32	0	31	Not estimable						
Total (95% CI)		32		31		Not estimable					
Total events	0		0								
Heterogeneity: Not app	plicable						0.01	0.1	1 1		100
Test for overall effect:				Fa		DGF/placebo	Favours p) lacel			

1.2.7.40 Recombinant platelet-derived growth factor: 3002g/g alternated with placebo versus 3002g/g

Figure 518: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients completely healed

	PDGF-BB/pla	PDGF-BE	300		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Rees 1999	6	32	1	30	100.0%	5.63 [0.72, 44.03]		
Total (95% CI)		32		30	100.0%	5.63 [0.72, 44.03]		
Total events	6		1					
Heterogeneity: Not ap	plicable					0.001 0.1 1 10 1000		
Test for overall effect:	Z = 1.65 (P = 0)	.10)					Favours PDGF-BB 300 Favours PDGF-BB/placebo	

Figure 519: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients ≥ 90% healed

	PDGF-BB/placebo		PDGF-BE	3 300		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI		
Rees 1999	19	32	12	30	100.0%	1.48 [0.88, 2.51]	+		
Total (95% CI)		32		30	100.0%	1.48 [0.88, 2.51]	-		
Total events	19		12						
Heterogeneity: Not ap	plicable						01 02 06 1 2 6 10		
Test for overall effect:	Z=1.48 (P=0	0.14)					Favours PDGF-BB 300 Favours PDGF-BB/placebo		

Figure 520: Recombinant platelet-derived growth factor: 300½g/g alternated with placebo versus 300½g/g – proportion of patients with osteomyelitis

	PDGF-BB/placebo		PDGF-BE	300		Peto Odds Ratio	Peto Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% Cl	Peto, Fix	ed, 95% CI	
Rees 1999	1	32	0	30	100.0%	6.94 [0.14, 350.54]			
Total (95% CI)		32		30	100.0%	6.94 [0.14, 350.54]			
Total events	1		0						
Heterogeneity: Not applicable 0.001 0.1 1 10 100									
Test for overall effect:	Z = 0.97 (P = 0)	1.33)			Favours PDGF-BB/placebo				